Have additional questions?
Connect with CSL Behring Medical Affairs to find additional information and ask questions.
Hizentra is indicated for maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) to prevent relapse of neuromuscular disability and impairment.
-Limitation of Use: Maintenance therapy in CIDP has been systematically studied for 6 months and for a further 12 months in a follow-up study. Continued maintenance beyond these periods should be individualized based on patient response and need for continued therapy.
Discover the latest innovation in Ig
*Based on equivalent dosing in grams. †Hizentra may be administered in 1 or 2 infusions over 1 or 2 consecutive days.
Experience IV-Related systemic adverse reactions
Have venous access issues
Require more frequent IV infusions
Seek flexibiltiy, freedom, and control
Photos do not depict actual patients
Below are areas you may find especially helpful when providing Hizentra to your patients.
Voluntary withdrawal of specific Hizentra vial lots.
Connect with CSL Behring Medical Affairs to find additional information and ask questions.